Although Nascimento et al. (56) showed that treatment with IL-17A antibody contributed to the control of Th1/Th2/Th17 inflammation, chemokine expression, extracellular matrix remodeling, and oxidative stress in a murine model of lipopolysaccharide-exacerbated asthma. This evidence concerns the gene IL17A and asthma.